In May 2024, the Blackstone Life Sciences portfolio company Uniquity Bio emerged from stealth with an FDA acceptance of its Phase II investigational new drug (IND) application for solrikitug, a monoclonal antibody targeting TSLP, and up to $300 million in capital from Blackstone to advance the asset in multiple indications.